ArticleJournal of cancer & allied specialties2026
Outcome of Autologous Stem Cell Transplant in Relapsed/Refractory Hodgkin Lymphoma - A Single Center Study.
Article in Journal of cancer & allied specialties, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL), the preferred treatment is autologous stem cell transplantation (ASCT) after receiving high-dose chemotherapy (HDC). Here, we describe and discuss the single-center experience, including outcomes and associated factors. Materials and Methods: To provide insight into our experience, our single-center retrospective cohort study included 33 patients (aged 18 years or older at the time of diagnosis) who received HDC/ASCT at Aga Khan University Hospital, Karachi, Pakistan, from January 2013 to December 2023. Results: Fourteen (42.4%) patients experienced post-transplant relapse, while 10 (30.3%) patients died. The transplant-related mortality (TRM) was seen in 2 (6.1%) patients. Median overall survival (OS) was 65 months, while the median progression-free survival (PFS) was 31 months. The 2-year PFS and OS were 62.1% (95% CI: 45.8-84.1%) and 77.9% (95% CI: 64.6-93.8%), respectively. On univariate analysis, factors associated with lower survival rates included a relapse within one year of initial chemotherapy and the failure to achieve complete remission (CR), both before and after transplantation. Multivariate analysis was not performed due to the small sample size and limited number of events. Conclusion: This study emphasizes that disease status before and after transplant affects outcomes, showing that achieving CR before ASCT yields better outcomes than achieving PR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.